Chronotherapy is a therapeutic approach that respects the circadian variations of physiological processes. The chronotherapeutic approach to hypertension has been shown to improve blood pressure (BP) control and reduce cardiovascular events. 1 Chronotherapy might be of similar importance in the treatment of elevated heart rate (HR). The 2016 statement of the Second Consensus Conference on the management of the hypertensive patients with elevated heart rate suggested that, based on previous trials, a HR higher than 80-85 bpm should be considered as elevated HR. 2 Increased HR is an independent risk factor for cardiovascular events and mortality in the general population and various cardiovascular pathologies. High HR was recently shown to be associated with a poor adherence to medication regimens in patients with resistant hypertension. 3 There are only a few prospective studies regarding the effect of HR reduction in heart failure and coronary artery disease. In hypertensive patients with high HR, retrospective analyses of studies with beta-blockers show no benefit of HR decrease in addition to blood pressure reduction, and prospective studies are not available. 2 The following two considerations may be of importance for hypertensive patients with elevated HR:
• First, nocturnal blood pressure seems to be of even greater prognostic value than its daytime counterpart and the chronotherapeutic approach to hypertension appears to be of utmost importance. In the MAPEC (Monitorizacion Ambulatoria para Prediccion de Eventos Cardiovasculares, i.e., ABPM for prediction of CVD events study), the shifting of intake of at least one of the antihypertensive medications from morning hours to bedtime improved BP control and remarkably reduced major cardiovascular events.
Lowering asleep systolic blood pressure and improving its decline towards the physiological nocturnal dipping profile were potentially the underlying pathomechanisms for the reduction of cardiovascular events. 1 The large multicentric Hygia study revealed that asleep SBP is the most significant BP-derived risk factor for CV events and an important therapeutic target. 4 Two ongoing trials, Both the potential danger of atrial fibrillation with ivabradine in patients with normal systolic function 11 and the pleiotropic effects of melatonin in terms of its chronobiotic nature and sympatholytic action, along with its generally good tolerability, 8, 12 may supposedly favour melatonin for the treatment of hypertensive patients with elevated HR.
It seems reasonable to suppose that the potential novel approach to slowing down HR with melatonin or ivabradine taken at bedtime might be a hopeful cardioprotective strategy in hypertensive patients with elevated HR.
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